VASSCA: Validation Study of the Simplified Seizure Classification Algorithm

Sponsor
Sándor Beniczky (Other)
Overall Status
Completed
CT.gov ID
NCT03796520
Collaborator
Danish Epilepsy Centre (Other), Shiraz University of Medical Sciences (Other), University of Pavia (Other), Thomas Jefferson University (Other)
240
5
19
48
2.5

Study Details

Study Description

Brief Summary

An algorithm has been developed for simplified classification of epileptic seizures, in order to optimize choice of antiepileptic drugs.

The objective of this study was to clinically validate the algorithm.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: EpiPick simplified seizure classification algorithm

Detailed Description

Optimal choice of antiepileptic drugs (AEDs) depend on the patients´ seizure-types. Over the last four decades, several classification systems have been proposed for epileptic seizures. The recent position paper of the International League Against Epilepsy defines 63 seizure-types. While this complex system might be useful for detailed phenotyping, currently there is no evidence that each of these seizure-types needs different clinical management strategy, and many clinicians find it difficult to implement.

To help physicians with optimizing the choice of AEDs, the investigators developed a simplified seizure classification, consisting of the minimal number of seizure-types, necessary for choice of AEDs, and the investigators developed an algorithm that identifies the patient´s seizure-type, based on a set of 10 simple questions, that can be answered by physicians even without extensive training in epilepsy. The current form of the algorithm was developed for patients whose seizures started in adolescence or adulthood (at the age of 10 years or older).

In this study, the investigators aim to validate the diagnostic algorithm, by comparing the seizure-type identified by the algorithm with the diagnosis and seizure-type as defined by trained experts, in the clinical workup of the patients.

Study Design

Study Type:
Observational
Actual Enrollment :
240 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Clinical Validation Study of the Simplified Seizure Classification Algorithm
Actual Study Start Date :
Jun 2, 2019
Actual Primary Completion Date :
Dec 31, 2020
Actual Study Completion Date :
Dec 31, 2020

Arms and Interventions

Arm Intervention/Treatment
Patients suspected for epilepsy

The cohort includes patients referred to the participating centers on suspicion of epilepsy, provided their seizure onset was at 10 years of age or older.

Diagnostic Test: EpiPick simplified seizure classification algorithm
EpiPick simplified seizure classification algorithm input: Grey matter brain lesion Exclusively nocturnal seizures First seizure at age > 20 years Lip smacking or chewing during seizures Staring with impaired awareness, lasting less than 20s without postictal confusion Sudden irregular jerks, in isolation or brief series, if none of the following applies: Are the jerks consistently in the same limb? When resting in bed when falling asleep? Bilateral tonic-clonic seizures within 1h of awakening or immediately preceded by irregular jerks Any of the following is present: Skin turning pale pre-ictally; Loss of consciousness immediately after urination or defecation; Sudden slump with loss of awareness, lasting less than 10 seconds; Seizure lasting longer than 10 minutes, with eyes closed throughout the seizure; Severe pre-ictal headache; Episodes consisting of falls that occur always after change in posture to the upright position, or coughing or feeling pain.

Outcome Measures

Primary Outcome Measures

  1. AC1 [Through study completion, an average of 8 months.]

    Agreement coefficient between index test (EpiPick) and the reference standard (expert classification)

Eligibility Criteria

Criteria

Ages Eligible for Study:
10 Years to 120 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  • patients referred to the participating centers on suspicion of epilepsy
Exclusion Criteria:
  • none

Contacts and Locations

Locations

Site City State Country Postal Code
1 Thomas Jefferson University Philadelphia Pennsylvania United States 19107
2 Aarhus University Hospital Aarhus Denmark 8000
3 Danish Epilepsy Centre Dianalund Denmark 4293
4 Shiraz University of Medical Sciences Shiraz Iran, Islamic Republic of
5 University of Pavia Pavia Italy 27100

Sponsors and Collaborators

  • Sándor Beniczky
  • Danish Epilepsy Centre
  • Shiraz University of Medical Sciences
  • University of Pavia
  • Thomas Jefferson University

Investigators

  • Principal Investigator: Sandor Beniczky, MD, PhD, Aarhus University Hospital
  • Principal Investigator: Guido Rubboli, MD, PhD, Danich Epilepsy Centre
  • Principal Investigator: Michael Sperling, MD, PhD, Thomas Jefferson University
  • Principal Investigator: Emilio Perucca, MD, PhD, University of Pavia
  • Principal Investigator: Ali A Asadi-Pooya, MD, PhD, Shiraz University of Medical Sciences

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Sándor Beniczky, professor, Aarhus University Hospital
ClinicalTrials.gov Identifier:
NCT03796520
Other Study ID Numbers:
  • EpiPick-1
First Posted:
Jan 8, 2019
Last Update Posted:
Feb 17, 2021
Last Verified:
Feb 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 17, 2021